NEW YORK (GenomeWeb News) – Agilent Technologies today said that its board of directors has authorized a new share repurchase program, which will become effective following the completion of its existing $1 billion share repurchase program.

The firm didn't say how much it expects to spend on the new repurchase program but stated that the goal is to "reduce or eliminate dilution resulting from issuances of stock under the company's employee equity incentive programs to maintain a share count of approximately 335 million diluted shares."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.